Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Punjab is grappling with an outbreak of leptospirosis, a rare bacterial disease, with 36 confirmed cases, including 19 children who have been hospitalized.

The outbreak is part of a larger water‑borne infection that has affected 110 people so far in Hazara Singh Wala, a border village in Ferozepur district. The hospitalized children are receiving care at Ferozepur Civil Hospital and are reported to be stable, according to media reports.

Leptospirosis spreads to humans through contact with the urine of infected animals such as dogs and rats. The disease previously made headlines in 2024 when Punjab Chief Minister Bhagwant Mann was hospitalized after contracting it.

The state health department reports that the outbreak is affecting mainly children and young people aged 3-25, with nearly 90 of the 110 symptomatic patients being minors, most of whom are school-going children, the Indian Express reported. Commonly reported symptoms include fever, abdominal pain, and jaundice.

Alarm was heightened in the district following the death of 12-year-old Sehaj Kaur from suspected Hepatitis E on February 24.

Investigations revealed that contaminated water, including rodent droppings and dead pigeons, contributed to the outbreak, causing widespread concern among villagers.

Media reports stated that health officials in the states are taking steps to prevent further spread of the outbreak. They are conducting house-to-house screenings, distributing chlorine tablets and oral rehydration solutions, as well as repairing water supply lines to contain the outbreak.

What Is Leptospirosis

Leptospirosis is usually a disease of animals like dogs, mostly rats, and some farm animals. It has also been reported in pigs, zebras, and horses.

It mainly spreads via contamination or through direct contact with loosely available food items or water infected with rat urine.

Common symptoms include:

• very high temperature
• headache
• muscular pains
• vomiting
• diarrhea
• yellow or brown patches in the eye,
• abdomen pain

While the disease is usually self-limiting and treatable with antibiotics, in severe cases it can spread to the kidney, brain, spinal cord, and liver and lead to death. It can also cause pulmonary haemorrhage, leading to respiratory failure and death.

Leptospirosis In India:

The neglected zoonotic disease is endemic to India due to a tropical climate that complements the transmission of infection.

The first disease outbreak was reported in the 1920s in the Andaman Islands.

As per the National Centre for Disease Control (NCDC), India is expected to report 0.1-1.0 million cases per year, but less than 10,000 cases are reported.

Only four states, i.e., Kerala, Gujarat, Tamil Nadu, and Maharashtra, report more than 500 cases per year as per IDSP Disease Alert.

Andaman, Andhra Pradesh, Assam, Goa, Delhi, Karnataka, Odisha, Puducherry, and Uttar Pradesh also report cases.

Due to a lack of awareness of the disease and a lack of suitable laboratory diagnostic capabilities in most regions of the country, leptospirosis has been under-reported and under-diagnosed in India.

An international group of scientists has created an artificial intelligence tool that can estimate a woman’s likelihood of developing breast cancer within the next four years.

The AI tool, known as the BRAIx risk score, analyzes mammogram images to generate an individualized risk assessment and flag women who may face a higher chance of developing the disease.

It may not only show the current risk but also predict the future risk, enabling early detection and treatments for a better outcome.

According to the findings published in The Lancet Digital Health journal, nearly one in 10 women ranked in the top 2 percent of risk by the AI tool were diagnosed with breast cancer within four years. This was despite previously receiving a clear screening result.

“These risk scores enable future development of personalized screening pathways to transform population breast cancer screening and save lives,” said corresponding author Helen M. L. Frazer of the University of Melbourne.

Frazer noted that identifying women who appear cancer-free but carry very high risk -- comparable to those with inherited BRCA1 or BRCA2 mutations -- will unravel both hereditary and non-hereditary causes of breast cancer.

From one-size-fits-all screening to personalization

Breast cancer screening programs have significantly lowered mortality rates -- by roughly 40-50 percent among women aged 50 to 74. However, most screening systems still apply the same approach to all women, regardless of individual risk.

Traditional screening tools use genetics, breast density, and questionnaires to estimate breast cancer risk. On the other hand, new AI-based screening tools, such as BRAIx personalizes screening by gathering information already present in breast scan images to better identify who is at higher risk.

“Our results show that conventional mammographic density is a far weaker predictor of breast cancer risk than the BRAIx risk score, even for interval cancers,” the researchers said in the paper. Interval cancers are aggressive tumors diagnosed after a negative mammogram.

The BRAIx Tool

The BRAIx risk score was developed using mammograms from nearly 400,000 women. To prove its efficacy, the AI tool was tested on data from almost 96,000 women from Australia and then confirmed in an independent Swedish population of over 4,500 women.

The findings showed that:

• The BRAIx risk score estimated breast cancer risk more accurately than the traditional risk factors, such as breast density, country of birth, and even family history.

• For the top 2 percent of women with the highest BRAIx risk score, the probability of a cancer diagnosis within 4 years was 9.7 percent -- a risk level exceeding that typically seen in women with inherited BRCA1 or BRCA2 mutations.

The BRAIx risk score can:

• Make breast screening more personalised,
• Improve early cancer detection,
• Reduce false alarms,
• Save lives without increasing costs

Global Breast Cancer Burden

Breast cancer continues to be the most common cancer among women worldwide.

A recent study published in The Lancet Oncology journal predicted that the number of new cases of the deadly disease will reach more than 3.5 million globally in 2050 -- rising by a third from 2.3 million in 2023.

Annual deaths from the disease will also rise by 44 percent -- from around 764,000 to 1.4 million.

However, not smoking, getting sufficient physical activity, lowering red meat consumption, and having a healthy weight can help prevent over a quarter of healthy years lost to illness and premature death from breast cancer.

Childhood obesity in India is expected to surge to a whopping 56 million by 2040 -- nearly a 20 percent rise from 2025, according to an alarming new global report released today by the World Obesity Federation.

The World Obesity Atlas 2026, released on World Obesity Day -- observed globally on March 4 -- revealed that of the 56 million, about 20 million children in the country will be obese, while the remaining will be overweight.

Globally, the number of children aged 5-19 years living with obesity or overweight is predicted to increase to 507 million by 2040 -- from 419 million in 2025.

Overweight Children: India Second-Highest Globally In 2025

Among children aged 5-9 years, 14.921 million were overweight or obese in 2025

In children aged 10-19 years, more than 26.402 million were overweight or obese.

India was among the top 10 countries -- second after China -- that accounted for over 200 million school-age children, aged 5-19 years, with high Body Mass Index (BMI).

Between 2010 and 2025, India had a 4.8 percent increase in the prevalence of high BMI and obesity among children aged 5-19 years.

"The increase in childhood obesity worldwide shows we have failed to take seriously a disease that affects one in five children," said Johanna Ralston, chief executive at the World Obesity Federation.

"Governments urgently need to step up prevention and management efforts for children living with overweight and obesity, and ensure that they receive the care they need," Ralston added.

High BMI To Surge Chronic Disease By 2040 In India

By 2040, the report also projected a substantial increase in the risk of diseases among children aged 5-19 years due to a high BMI in India. This includes:

• Hypertension (high blood pressure) expected to spike by 4.21 million from 2.99 million
• hyperglycemia (high blood sugar) to 1.91 million from 1.39 million
• high triglycerides (excess fats in the blood) to 6.07 million from 4.39 million
• metabolic dysfunction-associated steatotic liver disease (MASLD) to 11.88 million from 8.39 million

The key preventable risk factors in the country include:

• 74 percent of adolescents aged 11-17 fail to meet recommended physical activity levels
• Only 35.5 percent of school-age children (primary and secondary) receive school meals
• 32.6 percent of infants aged 1-5 months experience sub-optimal breastfeeding
• 13.4 percent of women aged 15-49 are exposed to high BMI
• 4.2 percent of women aged 15-49 live with Type 2 diabetes
• Children aged 6-10 consume an average of 0-50 ml of sugary drinks per day

Obesity: A Global Health Concern

Globally, the number of school-age children living with obesity now exceeds those living underweight.

Currently, more than one in five (20.7 per cent) 5-19 year-olds worldwide are living with obesity and overweight -- an increase from 14.6 per cent in 2010.

In 2025, about 177 million children aged 5-19 years were living with obesity. The number is expected to jump to 228 million in 2040.

By 2040, the Atlas also predicts that 227 million children aged 5-19 years will be living with obesity compared to 142 million living with underweight.

Notably, most of the world’s school-age children aged 5-19 living with obesity reside in the middle-income countries. By 2040, this is estimated to be as many as 169 million children.

Call To Action

The World Obesity Federation called for strong action to reverse current trends. These include imposing:

• taxes on sugar-sweetened beverages,
• restrictions on marketing to children (including digital platforms), implementation of global physical activity recommendations for children, protection of breastfeeding,
• healthier school food standards,
• integration of prevention and care into primary health systems.